Harding Thomas C.'s Form 4 filing
Clovis Oncology, Inc. (CLVS) · filed Nov 3, 2022
- Accession no.
- 0000899243-22-034896
- Filed
- Nov 3, 2022
- Trade date
- Nov 1-2, 2022
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 6 non-derivative transactions and 3 derivative transactions. Open-market sales total $1.73K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Harding Thomas C.CIK 0001834833 | Officer (See Remarks) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2022 | Common Stock | MOption exerciseAcquired | +1,562 | –F1 | – | 19,378 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −788 | $0.98F3 | −$772.24 | 18,590 | Direct | |
| Nov 1, 2022 | Common Stock | MOption exerciseAcquired | +1,812 | –F1 | – | 20,402 | Direct | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −915 | $0.98F3 | −$896.7 | 19,487 | Direct | |
| Nov 1, 2022 | Common Stock | MOption exerciseAcquired | +181 | –F1 | – | 3,864 | Indirect | |
| Nov 2, 2022 | Common Stock | SSaleDisposed | −63 | $0.98F4 | −$61.74 | 3,801 | Indirect |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 1, 2022 | Common Stock | MOption exerciseDisposed | −1,562 | $0.00 | $0 | 1,563 | Direct | |
| Nov 1, 2022 | Common Stock | MOption exerciseDisposed | −1,812 | $0.00 | $0 | 9,063 | Direct | |
| Nov 1, 2022 | Common Stock | MOption exerciseDisposed | −181 | $0.00 | $0 | 907 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
Each Restricted Stock Unit represents the right to receive one share of Common Stock.
Referenced by the price of 3 transactions in Table I.
- F3
This transaction was executed in multiple trades at prices ranging from $0.9621 to $0.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 2 transactions in Table I.
- F4
This transaction was executed in multiple trades at prices ranging from $0.9660 to $0.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 1 transaction in Table I.
Remarks
Senior Vice President and Chief Scientific Officer